Tissue-Specific Utilization of Menaquinone-4 Results in the Prevention of Arterial Calcification in Warfarin-Treated Rats

Journal of Vascular Research

Volumn 40, Issue 6, 2003, Pages 531-537

  Spronk, H M H ^a,b   Soute, B A M ^a   Schurgers, L J ^a   Thijssen, H H W ^a   De Mey, J G R ^a   Vermeer, C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Anticoagulants; Arteries; Atherosclerosis; Calcification; Extracellular matrix; Matrix Gla protein; Vascular smooth muscle cell; Vitamin K

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; DRUG DERIVATIVE; EPOXIDE; FARNOQUINONE; HEMOSTATIC AGENT; MENATETRENONE; PHYTOMENADIONE; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K GROUP; WARFARIN;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIOSCLEROSIS; ARTERY CALCIFICATION; ARTERY WALL; ARTICLE; CALCINOSIS; CALCULATION; CONTROLLED STUDY; DIETARY INTAKE; DRUG COMBINATION; ENDOPLASMIC RETICULUM; FEEDING; IN VITRO STUDY; LIVER; MALE; METABOLISM; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN LOCALIZATION; RAT; RAT STRAIN; TISSUE DISTRIBUTION; TISSUE SPECIFICITY;

ANIMALS; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; AORTA; ARTERIOSCLEROSIS; CALCINOSIS; DRUG THERAPY, COMBINATION; EPOXY COMPOUNDS; HEMOSTATICS; LIVER; MALE; RATS; RATS, INBRED WKY; TISSUE DISTRIBUTION; VITAMIN K 1; VITAMIN K 2; WARFARIN;

EID: 0442293394     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075344     Document Type: Article

References (23)

1. Shearer MJ: Vitamin K. Lancet 1995;345:229-234.
2. Vermeer C: Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J 1990;266:625-636.
3. Suttie JW: Recent advances in hepatic vitamin K metabolism and function. Hepatology 1987;7:367-376.
4. Fasco MJ, Hildebrandt EF, Suttie JW: Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 1982;257:11210-11212.
5. Wallin R, Cain D, Sane DC: Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells - A cell system which resembles the system in bone cells. Thromb Haemost 1999;82:1764-1767.
6. Price PA, Williamson MK, Haba T, Dell RB, Jee WS: Excessive mineralization with growth plate closure in rats on chronic warfarin treatment. Proc Natl Acad Sci USA 1982;79:7734-7738.
7. Price PA, Faus SA, Williamson MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998;18:1400-1407.
8. Price PA, Kaneda Y: Vitamin K counteracts the effect of warfarin in liver but not in bone. Thromb Res 1987;46:121-131.
9. Price PA, Faus SA, Williamson MK: Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 2000;20:317-327.
10. Ronden JE, Drittij-Reijnders MJ, Vermeer C, Thijssen HHW: Intestinal flora is not an intermediate in the phylloquinone-menaquinone-4 conversion in the rat. Biochim Biophys Acta 1998;1379:69-75.
11. Gelijnse JM, Vermeer C, Schurgers LJ, Grobbee DE, Pols HAP, Witteman JCM: Inverse association of dietary vitamin K-2 intake with cardiac events and aortic atherosclerosis: The Rotterdam Study. Abstracts of XVIIIth ISTH Congress. Thromb Haemost 2001, p 473.
12. Price PA, Faus SA, Williamson MK: Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001;21:817-824.
13. Thijssen HHW, Drittij Reijnders MJ: Vitamin K distribution in rat tissues: Dietary phylloquinone is a source of tissue menaquinone-4. Br J Nutr 1994;72:415-425.
14. Haroon Y, Bacon DS, Sadowski JA: Chemical reduction system for the detection of phylloquinone (vitamin K1) and menaquinones (vitamin K2). J Chromatogr 1987;384:383-389.
15. Thijssen HHW, Drittij Reijnders MJ, Fischer MA: Phylloquinone and menaquinone-4 distribution in rats: Synthesis rather than uptake determines menaquinone-4 organ concentrations. J Nutr 1996;126:537-543.
16. Kindberg CG, Suttie JW: Effect of various intakes of phylloquinone on signs of vitamin K deficiency and serum and liver phylloquinone concentrations in the rat. J Nutr 1989;119:175-180.
17. Groenen-van Dooren MMCL, Soute BAM, Jie KS, Thijssen HHW, Vermeer C: The relative effects of phylloquinone and menaquinone-4 on the blood coagulation factor synthesis in vitamin K-deficient rats. Biochem Pharmacol 1993;46:433-437.
18. Ronden JE, Thijssen HHW, Vermeer C: Tissue distribution of K-vitamers under different nutritional regimens in the rat. Biochim Biophys Acta 1998;1379:16-22.
19. Schurgers LJ, Vermeer C: Differential lipoprotein transport pathways of K-vitamins in healthy subjects. Biochim Biophys Acta 2002;1570:27-32.
20. Buitenhuis HC, Soute BA, Vermeer C: Comparison of the vitamins K1, K2 and K3 as cofactors for the hepatic vitamin K-dependent carboxylase. Biochim Biophys Acta 1990;1034:170-175.
21. Reedstrom CK, Suttie JW: Comparative distribution, metabolism, and utilization of phylloquinone and menaquinone-9 in rat liver. Proc Soc Exp Biol Med 1995;209:403-409.
22. Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M: Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: A double-blind placebo-controlled study. J Bone Miner Metab 1998;16:106-112.
23. Akiba T, Kurihara S, Tachibana K, Kuwahara M, Sakamoto H, Yoneshima H, Marumo F: Vitamin K (K) increased bone mass (BM) in hemodialysis patients (Pts) with low-turnover bone disease (LTOBD). J Am Soc Nephrol 1991;2:608.